Clinical Immunology Communications最新文献_第7页

Lower NK cell numbers in children with untreated juvenile dermatomyositis during the COVID-19 pandemic COVID-19大流行期间未经治疗的青少年皮肌炎儿童NK细胞数量降低

Clinical Immunology Communications Pub Date : 2023-12-01 Epub Date: 2023-02-18 DOI: 10.1016/j.clicom.2023.02.007

Christopher Costin , Gabrielle Morgan , Amer Khojah , Marisa Klein-Gitelman , Lauren M. Pachman

引用次数: 4

Aptamer: A theranostic approach towards breast cancer 适配体:一种治疗乳腺癌的方法

Clinical Immunology Communications Pub Date : 2023-12-01 Epub Date: 2023-06-03 DOI: 10.1016/j.clicom.2023.06.002

Shubhi Rana, Deepti Kaushik, Aprajita Singh, Deeksha Gautam, Janhavi Rai, Jitendra Singh Rathore

{"title":"Aptamer: A theranostic approach towards breast cancer","authors":"Shubhi Rana, Deepti Kaushik, Aprajita Singh, Deeksha Gautam, Janhavi Rai, Jitendra Singh Rathore","doi":"10.1016/j.clicom.2023.06.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.06.002","url":null,"abstract":"<div><p>Breast cancer has a heavy toll on the world's health, both in terms of morbidity and death. For women aged 35 to 54, it is the primary cause of mortality. In addition, over the preceding 2 decades, the mortality rate has not decreased noticeably. Early diagnosis and detection are still essential for enhancing patient outcomes despite substantial advancements in treatment. Also, possible to use monoclonal antibodies, but they come with a host of drawbacks, including unspecified binding, toxicity, expense, and debated clinical efficacy. Aptamers, which are small nucleic acid molecules that can bind to specific target molecules with high specificity, have instead emerged as potential theranostic treatments for breast cancer. Both for diagnosis and treatment, aptamers can be made to precisely target breast cancer cells or molecules linked to tumor progression. High binding affinity and specificity, low immunogenicity, and ease of modification are just a few of the characteristics that set aptamers apart from other delivery systems and make them desirable options for the delivery of drugs, imaging agents, or both, to breast cancer cells. In this study, we provide a comprehensive overview of the aptamer-based theranostic strategies for treating breast cancer, including aptamer selection, modifications, and imaging and drug delivery applications.</p><p>We also discussed the SELEX method for picking aptamers and why they are good breast cancer treatments. The toxicity and weak immunogenicity of some antigens do not affect aptamer selection, unlike antibodies. Compared to antibodies, they are more selective and have higher affinities. Therefore, in the future, these therapies may be used as both main therapies and adjuvants to traditional anti-HER2 therapies. We also discussed the difficulties and potential futures of theranostic approaches based on aptamers for treating breast cancer.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"3 ","pages":"Pages 61-73"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49767283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum to “A case of de novo seronegative inflammatory oligoarthritis associated with COVID-19 infection” Clinical Immunology Communications 2 (2022) 159–161/ “1例新发血清阴性炎性少关节炎合并COVID-19感染”临床免疫通讯2 (2022)159-161 /

Clinical Immunology Communications Pub Date : 2023-12-01 Epub Date: 2023-04-14 DOI: 10.1016/j.clicom.2023.03.001

Lily H. Sung , Natalya Surmachevska , Jose E. Rubio

引用次数: 0

GROWTH HORMONE, IMMUNOSENESCENCE AND VACCINATION FAILURE IN THE ELDERLY 老年人的生长激素、免疫衰老和疫苗接种失败

Clinical Immunology Communications Pub Date : 2023-12-01 Epub Date: 2023-02-10 DOI: 10.1016/j.clicom.2023.02.005

José E Belizário, Miguel Garay-Malpartida

{"title":"GROWTH HORMONE, IMMUNOSENESCENCE AND VACCINATION FAILURE IN THE ELDERLY","authors":"José E Belizário, Miguel Garay-Malpartida","doi":"10.1016/j.clicom.2023.02.005","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.02.005","url":null,"abstract":"<div><p>In the aging population, the longitudinal decrease in the secretion of steroidal and polypeptides growth hormones is directly associated with accumulation of senescent cells in tissues and organs. The cellular hypo-replicative senescence state is caused by metabolic stress and persistent DNA damage, which lead to the activation of the p16<sup>INK4a</sup> cell-cycle inhibitor, retinoblastoma and p53 pathways. Aging increases the susceptibility to physical frailty, sarcopenia, diabetes, atherosclerosis, infectious disease and cancer in the older adults. As a consequence of immunosenescence and reduced immunoreactivity of the innate and adaptive systems, seniors have a weak response to vaccination. The high doses of vaccines have been recommended to boost growth and activation of memory T and B cells in non-responsive older individuals, but it is not sufficient for long-term protection. The treatment with recombinant human growth hormone has been shown to regenerate thymus and increase the repertoire of naive T cells CD4+ and CD8+ T cell and B cell subsets in people with age-related diseases, chronic viral infection and immunodeficiencies. This review presents an update on senescence biology and their clinical immunological manifestations in the elderly. We describe possible immune mechanisms by which personalized recombinant growth hormone therapy could act to prolong the effectiveness of the vaccines recommended to older adults.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"3 ","pages":"Pages 51-57"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49765148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Time-series COVID-19 policy outcome analysis of the 50U.S. states 美国50个州COVID-19政策结果的时序分析。州

Clinical Immunology Communications Pub Date : 2023-08-23 DOI: 10.1016/j.clicom.2023.08.002

Yoshiyasu Takefuji , Junya Toyokura

引用次数: 0

Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS 促进肺内皮和上皮修复和抗促炎细胞因子的新方法可能是未来治疗ARDS的有希望的药物

Clinical Immunology Communications Pub Date : 2023-07-28 DOI: 10.1016/j.clicom.2023.07.005

Montaser Alrjoob , Alaa Alkhatib , Rana Padappayil , Husam Bader , Doantrang Du , Chandler Patton

{"title":"Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS","authors":"Montaser Alrjoob , Alaa Alkhatib , Rana Padappayil , Husam Bader , Doantrang Du , Chandler Patton","doi":"10.1016/j.clicom.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.005","url":null,"abstract":"<div><p>The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of noncardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation. ARDS occurs most often in the setting of pneumonia, sepsis, aspiration of gastric contents or severe trauma, and is present in ∼10% of all intensive care unit patients worldwide. Pathologic specimens from patients with ARDS most frequently reveal diffuse alveolar damage, and laboratory studies have demonstrated both alveolar epithelial and lung endothelial injury, resulting in accumulation of protein-rich inflammatory edema fluid in the alveolar space. The current therapeutic regimen is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%.This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 45-50"},"PeriodicalIF":0.0,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study 中老年个体血清免疫球蛋白水平和抗生素处方风险:一项基于人群的队列研究

Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.003

Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse

{"title":"Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study","authors":"Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse","doi":"10.1016/j.clicom.2023.07.003","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.003","url":null,"abstract":"<div><h3>Objectives</h3><p>Elderly become more susceptible to lower respiratory tract infections, resulting in antibiotic prescriptions. Immunoglobulins (Ig) play an important role in host defense and protection against infections. Therefore, we aimed to investigate whether lower Ig levels are a risk factor for antibiotic use in the general elderly population.</p></div><div><h3>Methods</h3><p>After exclusion of current antibiotic users, Cox proportional-hazards regression models were performed to investigate the effect of stable serum IgM, IgG and IgA levels on time to first antibiotic prescription within the Rotterdam Study. Regression models were adjusted for age, sex, body mass index, smoking status and diabetes. We introduced quadratic terms and additionally categorized Igs to explore and quantify potential non-linearity of the association. The restricted cubic splines technique was used to plot the natural log of the hazard across Ig level.</p></div><div><h3>Results</h3><p>In total, 8,639 participants were included (mean age 64 years, 57% female, medium follow-up 3.2 years). No significant association between IgM and time to antibiotic prescription was observed. IgG and IgA levels (in g/L) showed a U-shaped relationship with time to antibiotic prescription (linear IgG HR 0.959, 95% CI 0.930–0.989; quadratic IgG² HR 1.002, 95% CI 1.000–1.003; linear IgA HR 0.949, 95% CI 0.910–0.990; quadratic IgA² HR 1.009, 95% CI 1.004–1.013).</p></div><div><h3>Conclusion</h3><p>Both low and high IgG and IgA levels were associated with a higher incidence of antibiotic prescriptions in stable middle-aged and older individuals. Increased awareness for the potential increased infection risk when persons have low or high Ig levels, even within the reference ranges, is needed.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 23-29"},"PeriodicalIF":0.0,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49752593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 2: Sézary syndrome 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制。第二部分:ssamzary综合征

Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.002

Nina C. Nwade , Sachi I. Desse , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Jillian M. Richmond , Angel S. Byrd

引用次数: 0

IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials IL-23抑制剂治疗银屑病关节炎:随机对照试验的系统回顾和荟萃分析

Clinical Immunology Communications Pub Date : 2023-07-20 DOI: 10.1016/j.clicom.2023.07.001

Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan

{"title":"IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials","authors":"Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan","doi":"10.1016/j.clicom.2023.07.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.001","url":null,"abstract":"<div><h3>Aim</h3><p>To review the available evidence on the efficacy and safety profiles of four Interleukin-23 inhibitors in patients with Psoriatic Arthritis.</p></div><div><h3>Methods</h3><p>Several databases were searched till July 2022. A total of 11 RCTs with at least one treatment arm were included. All articles were in English. The primary outcomes were ACR20, HAQ-DI, PASI90, and TEAEs experienced by the patients.</p></div><div><h3>Results</h3><p>Compared to other groups, Guselkumab had the strongest association with ACR20 response (RR: 2.14; 95% CI: 1.84-2.49, <em>p < 0.00001</em>), while a mean change in HAQ-DI (MD: -0.24; 95% CI: -0.41- -0.13, <em>p = 0.0001</em>) and PASI90 (RR: 9.81; 95% CI: 3.18-30.22; <em>p <0.01</em>) were most strongly associated with Ustekinumab. TEAEs were significantly present in the Guselkumab group (RR: 1.26; 95% CI: 1.00 - 1.59; <em>p = 0.05</em>).</p></div><div><h3>Conclusion</h3><p>Although our analysis suggests that IL-23 inhibitors are efficacious at treating psoriatic arthritis, further studies are required for long-term outcomes.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 7-22"},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature 子宫内暴露于利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松(R-CHOP)免疫调节化疗后的婴儿B细胞耗竭:病例系列和文献回顾

Clinical Immunology Communications Pub Date : 2023-06-22 DOI: 10.1016/j.clicom.2023.06.004

Jantien W. Wieringa , Mirjam J. Esser , Jan G.M.C. Damoiseaux , Gertjan A. Driessen , Joyce J.B.C. van Beers

引用次数: 1